AstraZeneca (NASDAQ:AZN) Stock Acquired Rep. Lisa C. McClain

Representative Lisa C. McClain (R-Michigan) recently bought shares of AstraZeneca PLC (NASDAQ:AZN). In a filing disclosed on November 21st, the Representative disclosed that they had bought between $1,001 and $15,000 in AstraZeneca stock on October 30th. The trade occurred in the Representative’s “CHARLES SCHWAB 401K > SCHWAB 893” account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Coherent (NYSE:COHR) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Clorox (NYSE:CLX) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Northern Trust (NASDAQ:NTRS) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Honda Motor (NYSE:HMC) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Home BancShares (NYSE:HOMB) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Five Below (NASDAQ:FIVE) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Pure Storage (NYSE:PSTG) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of BHP Group (NYSE:BHP) on 10/31/2025.

AstraZeneca Trading Up 0.1%

NASDAQ AZN traded up $0.08 on Thursday, hitting $93.32. 4,656,008 shares of the stock were exchanged, compared to its average volume of 5,159,645. The company’s 50-day moving average price is $84.22 and its two-hundred day moving average price is $77.46. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.86 and a quick ratio of 0.67. AstraZeneca PLC has a 52-week low of $61.24 and a 52-week high of $94.02. The company has a market capitalization of $289.43 billion, a price-to-earnings ratio of 35.08, a P/E/G ratio of 1.52 and a beta of 0.34.

AstraZeneca (NASDAQ:AZN) last issued its earnings results on Thursday, November 6th. The company reported $1.19 EPS for the quarter, topping the consensus estimate of $1.14 by $0.05. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%.The business had revenue of $15.19 billion during the quarter, compared to analysts’ expectations of $14.75 billion. During the same quarter last year, the firm posted $2.08 earnings per share. AstraZeneca’s revenue was up 12.0% compared to the same quarter last year. Research analysts predict that AstraZeneca PLC will post 4.51 EPS for the current year.

Institutional Investors Weigh In On AstraZeneca

Several institutional investors and hedge funds have recently modified their holdings of the business. CIBC Bancorp USA Inc. acquired a new position in AstraZeneca during the third quarter worth $1,650,000. Oarsman Capital Inc. increased its holdings in shares of AstraZeneca by 9.1% during the 3rd quarter. Oarsman Capital Inc. now owns 25,461 shares of the company’s stock valued at $1,953,000 after acquiring an additional 2,132 shares during the last quarter. Centaurus Financial Inc. raised its stake in shares of AstraZeneca by 5.2% in the 3rd quarter. Centaurus Financial Inc. now owns 7,419 shares of the company’s stock valued at $569,000 after acquiring an additional 366 shares in the last quarter. First Affirmative Financial Network lifted its holdings in AstraZeneca by 10.3% in the 3rd quarter. First Affirmative Financial Network now owns 12,685 shares of the company’s stock worth $973,000 after purchasing an additional 1,181 shares during the last quarter. Finally, Advisory Services Network LLC boosted its position in AstraZeneca by 1.3% during the third quarter. Advisory Services Network LLC now owns 20,191 shares of the company’s stock worth $1,549,000 after purchasing an additional 256 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have commented on AZN. Deutsche Bank Aktiengesellschaft lowered AstraZeneca from a “hold” rating to a “sell” rating in a research report on Thursday, October 16th. Jefferies Financial Group began coverage on shares of AstraZeneca in a report on Monday, October 27th. They set a “buy” rating for the company. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of AstraZeneca in a research note on Wednesday, October 8th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $86.00.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.